HC Wainwright Cuts Evommune (NYSE:EVMN) Price Target to $50.00

Evommune (NYSE:EVMN) had its price objective trimmed by HC Wainwright from $65.00 to $50.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Evommune’s Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($3.00) EPS and FY2027 earnings at ($3.30) EPS.

A number of other equities research analysts have also weighed in on EVMN. The Goldman Sachs Group upgraded shares of Evommune to a “buy” rating in a research note on Wednesday, January 7th. Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Cantor Fitzgerald started coverage on Evommune in a report on Monday, December 1st. They issued an “overweight” rating for the company. Weiss Ratings assumed coverage on Evommune in a research report on Tuesday, February 3rd. They set a “sell (e)” rating for the company. Finally, Royal Bank Of Canada raised Evommune to a “moderate buy” rating in a report on Tuesday, March 10th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $47.17.

Evommune Price Performance

Shares of EVMN stock opened at $23.35 on Wednesday. The business has a 50 day moving average of $23.32. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20. The company has a market capitalization of $840.99 million and a price-to-earnings ratio of -2.89.

Evommune (NYSE:EVMN) last released its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Institutional Trading of Evommune

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EQT Fund Management S.a r.l. bought a new position in shares of Evommune in the fourth quarter worth about $84,395,000. RA Capital Management L.P. bought a new position in shares of Evommune during the 4th quarter valued at approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new position in shares of Evommune during the 4th quarter valued at approximately $32,989,000. Nan Fung Group Holdings Ltd purchased a new stake in Evommune in the 4th quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. purchased a new stake in Evommune in the 4th quarter worth approximately $22,408,000.

Key Stories Impacting Evommune

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: Clear Street / Clear Str initiated coverage / upgraded Evommune with a buy / strong-buy stance, which can attract demand from momentum and growth-focused funds. Clear Street initiates coverage of Evommune (EVMN) with buy recommendation
• Neutral Sentiment: A market/industry article about Planet Labs was also logged in the feed but is unrelated to Evommune’s fundamentals or near-term catalysts. Traders are unlikely to move EVMN based on that piece. Planet Labs (NYSE:PL) Revenue Beats, Lags NYSE Index on Profit
• Negative Sentiment: HC Wainwright sharply cut its quarterly and full-year EPS forecasts for 2026–2027 (FY2026 EPS from prior -$1.40 to -$3.00; FY2027 -$3.30) while keeping a “Buy” rating and $50 price target. The large downward revisions signal higher expected cash burn or slower progress on clinical/commercial milestones, which is a clear near-term negative for valuation and could pressure the stock despite the buy rating. HC Wainwright Issues Pessimistic Forecast for Evommune (NYSE:EVMN) Stock Price
• Negative Sentiment: Additional outlets reported Clear Str/other firms’ upgrades (e.g., Zacks/TickerReport) but these are outweighed by the magnitude of HC Wainwright’s downward EPS revisions; the net effect today appears to be defensive selling and profit-taking. TickerReport coverage of Clear Str upgrade

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.